- 1030613-07-0Ethyl 5-bromo-1,3,4-thiadiazole-2-carboxylate
- 103065-19-6D-Prallethrin
- 103068-18-4Magnesium,[1,1'-biphenyl]-3-ylbromo-
- 103068-20-81-Bromo-3,5-diphenylbenzene
- 103068-40-21,3-Benzenediol,2-fluoro-
- 103068-41-31,3-Benzenediol,4-fluoro-
- 103068-64-01H-Pyrazol-5-amine,1,3-dimethyl-, hydrochloride (1:1)
- 103069-50-71-Piperazineethanol,4-(1-methylethyl)-
- 10307-26-31-Hexanesulfonic acid,methyl ester
- 10307-60-5Butanoic acid,2-methyl-, methyl ester, (2S)-
Hot Products
- 80-73-91,3-Dimethyl-2-imidazolidinone
- 68497-62-11-Pyrrolidineacetamide,N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-
- 6284-40-8D-Glucitol,1-deoxy-1-(methylamino)-
- 114-07-8Erythromycin
- 139264-17-8Zolmitriptan
- 104344-23-2Bisoprolol fumarate
- 2234-16-42',4'-Dichloroacetophenone
- 33818-15-4Cytidine5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl] ester, inner salt,sodium salt (1:1)
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
|
Basic Information |
|
Post buying leads |
|
Suppliers |
| Name |
Daptomycin |
EINECS | 600-389-2 |
| CAS No. | 103060-53-3 | Density | 1.45 g/cm3 |
| PSA | 702.02000 | LogP | 0.88280 |
| Solubility | N/A | Melting Point |
202-204?C |
| Formula | C72H101 N17 O26 | Boiling Point | 2078.2 °C at 760 mmHg |
| Molecular Weight | 1620.69 | Flash Point | 1210.7 °C |
| Transport Information | N/A | Appearance | White powder |
| Safety | Risk Codes | N/A | |
| Molecular Structure |
|
Hazard Symbols | N/A |
| Synonyms |
Benzenebutanoic acid, N-(1-oxodecyl)-L-tryptophyl-D-asparaginyl-L-a-aspartyl-L-threonylglycyl-L-ornithyl-L-a-aspartyl-D-alanyl-L-a-aspartylglycyl-D-seryl-(3R)-3-methyl-L-a-glutamyl-a,2-diamino-g-oxo-, (13?;4)-lactone, (aS)-;Cidecin;Cubicin;Dapcin;Daptomicina;Daptomycine;Daptomycinum;Deptomycin;LY 146032;N-(1-Oxodecyl)-L-tryptophyl-D-asparaginyl-L-a-aspartyl-L-threonylglycyl-L-ornithyl-L-a-aspartyl-D-alanyl-L-a-aspartylglycyl-D-seryl-(3R)-3-methyl-L-a-glutamyl-(aS)-a,2-diamino-g-oxobenzenebutanoicacid (13?; |
Daptomycin Synthetic route
- 334-48-5
1-decanoic acid
- 29022-11-5
N-(fluoren-9-ylmethoxycarbonyl)glycine
- 1429504-34-6
(2S,3R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-3-methyl-5-oxopentanoic acid
- 35661-38-2, 35661-39-3, 79990-15-1
N-(9-fluorenylmethoxycarbonyl)-D-alanine
- 73731-37-0
Fmoc-Thr-OH
- 73724-45-5, 136083-72-2, 116861-26-8
(R)-N-(fluoren-9-ylmethoxycarbonyl)serine
- 109425-55-0
Fmoc-Orn(Boc)-OH
- 88223-98-7
p-toluenesulfonic acid salt of glycine allyl ester
- 144120-53-6
(S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(allyloxy)-4-oxobutanoic acid
- 144120-52-5
4-(1,1-dimethylethyl) ester of Nα-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-aspartic acid allyl ester
- 333366-23-7
(S)-(−)-4-tert-butyl 2-azidosuccinic acid
- 103060-53-3
daptomycin
| Conditions | Yield |
|---|---|
| Stage #1: (S)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(allyloxy)-4-oxobutanoic acid With N-ethyl-N,N-diisopropylamine In dichloromethane for 4h; 2-chlorotrityl chloride resin; Stage #2: With tetrakis(triphenylphosphine) palladium(0); 1,3-dimethylbarbituric acid In dichloromethane; N,N-dimethyl-formamide for 1h; 2-chlorotrityl chloride resin; Stage #3: 1-decanoic acid; N-(fluoren-9-ylmethoxycarbonyl)glycine; (2S,3R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-(tert-butoxy)-3-methyl-5-oxopentanoic acid; C23H20N4O3; C62H58N4O15; N-(9-fluorenylmethoxycarbonyl)-D-alanine; Fmoc-Thr-OH; (R)-N-(fluoren-9-ylmethoxycarbonyl)serine; Fmoc-Orn(Boc)-OH; p-toluenesulfonic acid salt of glycine allyl ester; 4-(1,1-dimethylethyl) ester of Nα-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-aspartic acid allyl ester; (S)-(−)-4-tert-butyl 2-azidosuccinic acid; (S)-2-azido-3-(1-(tert-butoxycarbonyl)-1H-indol-3-yl)propanoic acid Further stages; | 9% |
| Conditions | Yield |
|---|---|
| In aq. buffer at 37℃; for 12h; pH=8; | 60% |
| Conditions | Yield |
|---|---|
| Stage #1: C82H102N6O16 With 4-methyl-morpholine; isobutyl chloroformate In tetrahydrofuran at 0℃; for 1h; Stage #2: daptomycin With sodium hydrogencarbonate In tetrahydrofuran; water at 0 - 20℃; | 48% |
- 159857-81-5
N-[6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]-L-valyl-N5-carbamoyl-N[4-({[(4-nitrophenoxy)carbonyl]oxy}methyl)phenyl]-L-ornithinamide
- 103060-53-3
daptomycin
| Conditions | Yield |
|---|---|
| With benzotriazol-1-ol; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; Sealed tube; | 44% |
| Conditions | Yield |
|---|---|
| With sodium hydrogencarbonate In tetrahydrofuran; water at 20℃; for 20h; | 37% |
| Conditions | Yield |
|---|---|
| In aq. buffer at 37℃; for 12h; pH=8; | 6% |
Daptomycin History
Daptomycin (CAS NO.103060-53-3) was originally discovered by researchers at Eli Lilly and Company in the 1980s, who designated the compound LY 146032. It showed promise in Phase I/II clinical trials for the treatment of infections caused by Gram-positive organisms. However, high dose therapy was found to be associated with adverse effects on skeletal muscle, including myalgia and the potential for myositis, and Lilly ceased development. The rights to LY 146032 were subsequently acquired by Cubist Pharmaceuticals in 1997. Food and Drug Administration (FDA) approval in September 2003. Daptomycin is marketed in the EU and several other countries by Novartis following its buying of Chiron Corporation. Outside of the US, Daptomycin is available in Canada and many European countries, with further launches expected in 2008.
Daptomycin Specification
1. Introduction of Daptomycin
Daptomycin is one kind of white crystalline powder, odorless, little bitter taste. If you want to keep it, it should be stored in cool and dry places, keep away from light. Besids, this chemical belongs to the Product Category which include Antibacterial; Intermediates & Fine Chemicals; Pharmaceuticals. In addition, Daptomycin is a naturally-occurring compound found in the soil saprotroph Streptomyces roseosporus.
2. Properties of Daptomycin
Daptomycin has the following property datas: (1)Density: 1.45 g/cm3; (2)Index of Refraction: 1.638; (3)Flash Point: 1210.7 °C; (4)Enthalpy of Vaporization: 366.93 kJ/mol; (5)Boiling Point: 2078.2 °C at 760 mmHg.
3. Structure Descriptors of Daptomycin
You could convert the following datas into the molecular structure:
(1). InChI: InChI=1S/C72H101N17O26/c1-5-6-7-8-9-10-11-22-53(93)81-44(25-38-31-76-42-20-15-13-17-39(38)42)66(108)84-45(27-52(75)92)67(109)86-48(30-59(102)103)68(110)89-61-37(4)115-72(114)49(26-51(91)40-18-12-14-19-41(40)74)87-71(113)60(35(2)24-56(96)97)88-69(111)50(34-90)82-55(95)32-77-63(105)46(28-57(98)99)83-62(104)36(3)79-65(107)47(29-58(100)101)85-64(106)43(21-16-23-73)80-54(94)33-78-70(61)112/h12-15,17-20,31,35-37,43-50,60-61,76,90H,5-11,16,21-30,32-34,73-74H2,1-4H3,(H2,75,92)(H,77,105)(H,78,112)(H,79,107)(H,80,94)(H,81,93)(H,82,95)(H,83,104)(H,84,108)(H,85,106)(H,86,109)(H,87,113)(H,88,111)(H,89,110)(H,96,97)(H,98,99)(H,100,101)(H,102,103)/t35?,36-,37?,43+,44+,45+,46+,47+,48+,49+,50-,60+,61?/m1/s1
(2). InChIKey: InChIKey=DOAKLVKFURWEDJ-OFNKPWESSA-N
(3). Smiles: C(=O)(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NC1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)OC1C)CC(=O)c1ccccc1N)[C@@H](CC(=O)O)C)CO)C)CC(=O)O)CCCN)CC(=O)O)CC(=O)N)Cc1c[nH]c2c1cccc2)CCCCCCCCC
4. Use of Daptomycin
Daptomycin is a novel lipopeptide antibiotic used in the treatment of certain infections caused by Gram-positive organisms. Its distinct mechanism of action means that it may be useful in treating infections caused by multi-resistant bacteria.
What can I do for you?
Get Best Price
